Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-07
2007-08-07
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S424000, C548S213000, C548S551000
Reexamination Certificate
active
10536303
ABSTRACT:
The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.
REFERENCES:
patent: 5545640 (1996-08-01), Beaulieu et al.
patent: 5811581 (1998-09-01), Piva et al.
patent: 5866100 (1999-02-01), Tournier et al.
patent: 5968942 (1999-10-01), Vazquez et al.
patent: 6248775 (2001-06-01), Vazquez et al.
patent: 2003/0004360 (2003-01-01), Reeder
patent: 2004/0171881 (2004-09-01), John et al.
patent: 4109169 (1992-09-01), None
patent: 19817461 (1999-10-01), None
patent: 19818614 (1999-10-01), None
patent: 0663391 (1997-04-01), None
patent: 511087 (1999-08-01), None
patent: 9801901 (1999-08-01), None
patent: 9206691 (1992-05-01), None
patent: 9404492 (1994-03-01), None
patent: 9414478 (1994-07-01), None
patent: 9506030 (1995-03-01), None
patent: 9619437 (1996-06-01), None
patent: 9722365 (1997-06-01), None
patent: 9730788 (1997-08-01), None
patent: 9825883 (1998-06-01), None
patent: 9833795 (1998-08-01), None
patent: 9925686 (1999-05-01), None
patent: 9954305 (1999-10-01), None
patent: 0144213 (2001-06-01), None
patent: 0170672 (2001-09-01), None
patent: 0202505 (2002-01-01), None
patent: 0202512 (2002-01-01), None
patent: 0202518 (2002-01-01), None
patent: WO02/02506 (2002-01-01), None
patent: 03040096 (2003-05-01), None
Alker et al., Application of Enantiopure Templated Azomethine Ylids to β-Hydroxy-α-amino Acid Synthesis, Tetrahedron 54:6089-6098 (1998).
Berg et al., Acylation of 2,2,2,6,6-Tetramethylpiperidine and 2,2,5,5-Tetramethylpyrrolidine, J. Chem. Soc. C 1654-1658 (1971).
Berge et al., Pharmaceutical Salts, Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
Bertus et al., New and easy route to primary cyclopropylamines from nitriles, Chem. Commun. 16:1792-1973 (2001).
Cai et al., BACE1 is the major β-sectetase for generation of Aβ peptides by neurons, NatureNeuroscience4(3):233-234 (2001).
Connor, Cathepsin D, Handbook of Proteolytic Enzymes pp. 828-836 (1998).
Dalla Croce et al., Stereoselective synthesis of 3-heteroaromatic-substituted alanines, Tetrahedron:Asymmetry11:2635-2642 (2000).
De Strooper et al., A firm base for drug development, Nature 402:471-472 (1999).
Fleisher et al., Improved oral drug delivery: solubility limitation overcome by the use of prodrugs, Advanced Drug Delivery Reviews 19:115-130 (1996).
Greene et al., The Role of Protective Groups in Organic Synthesis, Protective Groups in Organic Synthesis, 3rded., 1-16 (1999).
Higuchi et al., Pro-drugs as Novel Drug Delivery Systems, ACS Symposium Series 14, American Chemical Society pp. 14-15 (1975).
Jacquier et al., Bulletin de la Societe Chimique de France (Mousseron) 596600 (1957) (FR).
Koelsch, A Synthesis of 3-Phenylpiperidines, J. of Am. Chem. Soc. 65:2093-2095 (1943).
Luo et al., Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation, NatureNeuroscience4(3):231-232 (2001).
Kerins et al., Generation of Substituted Styrenes via Suzuki Cross-Coupling of Aryl Halides with 2,4,6-Trivinylcyclotriboroxane, J. Org. Chem. 67:4968-4971 (2002).
Morris et al., Vinyl Sulfonyl Esters and Amides in the Synthesis of Substituted δ-Sultams and δ-Sultones, J. Org. Chem. 56:3549-3556 (1991).
Roberds et al., BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics, Human Molecular Genetics 10(12):1317-1324 (2001).
Naslund et al., Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline, JAMA 283(12):1571-1577 (2000).
Selkoe, Alzheimer's Disease: Genes, Proteins, and Therapy, Physiological Reviews 81(2):741-766 (2001).
Tani et al., Development of a Highly Selective EP2-Receptor Agonist. Part 1: Identification of 16-hydroxy-17,17-trimethylene PGE2Derivatives, Bioorganic & Medicinal Chemistry 10:1093-1106 (2002).
Tsuri et al., A Novel Class of Platelet Activating Factor (PAF) Antagonists. I. Synthesis and Structure-Activity Studies on PAF-Sulfonamide Isosteres, Chem Pharm. Bull. 40(1):75-84 (1992).
Vassar et al., Aβ-Generating Enzymes: Recent Advances in β- and γ-Secretase Research, Neuron 27:419-422 (2000).
Younkin, Amyloid β vaccination: reduced plaques and improved cognition, Nature Medicine 7(1):18-19 (2001).
Demont Emmanuel H
Faller Andrew
MacPherson David Timothy
Milner Peter Henry
Naylor Alan
Deppenbrock Bonnie L.
Glaxo Group Limited
Saeed Kamal A.
LandOfFree
Hydroxyethylamine derivatives for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxyethylamine derivatives for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyethylamine derivatives for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3865162